Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, announced that the first patient has been dosed in its Phase 1 clinical study evaluating IAM1363, a selective and brain-penetrant inhibitor of HER2 signaling for the treatment of HER2-driven cancers.
“Using Iambic’s AI platform, we have...
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for...
Biodesix, Inc., a leading diagnostic solutions company with a focus in lung diseases, announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving...
A2 Biotherapeutics, Inc., a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to address the high unmet needs in cancer, announced the appointment of James Robinson as its Chief Executive Officer and a member of its Board of Directors, effective April 1st, 2024. Robinson succeeds Scott Foraker, A2...
VRG50635 is one of the first clinical-stage drugs discovered and developed entirely using an AI-powered platform
Verge Genomics, a leading clinical-stage biotechnology company, and Ferrer, a global pharmaceutical B Corp company with a growing focus on rare neurological disorders, have announced a strategic collaboration for the co-development of VRG50635, Verge's...
AI combined with expert guidance to better support medical affairs by delivering insights rooted in real data for more impactful communications
Lumanity, a global life sciences strategic services partner, and Sorcero, a leading provider of advanced AI solutions purpose-built for life sciences, announced a partnership to deliver AI-powered medical strategy...
Profluent, an AI-first protein design company, announced the close of additional funding to bring the total raised to $44M. The $35M financing was led by Spark Capital, with participation from existing investors Insight Partners and Air Street Capital along with a syndicate of angel investors from OpenAI, Salesforce, Octant Bio,...
Acquisition of MotionHall reinforces strategy to lead market-specific solutions, including workflows and expert services fuelled by industry vertical AI
Clarivate Plc a leading global provider of transformative intelligence, has announced an agreement to acquire the substantial majority of assets of MotionHall, a Silicon Valley technology start-up company serving the life sciences...
Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality...
Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™.
IPA, an artificial intelligence-driven biotherapeutic research and technology company, announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument...
